PD
Point72 (DIFC) Portfolio holdings
AUM
$1.25B
1-Year Return
9.31%
This Quarter Return
+5.32%
1 Year Return
+9.31%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$1.25B
AUM Growth
+$216M
(+21%)
Cap. Flow
+$158M
Cap. Flow
% of AUM
12.56%
Top 10 Holdings %
Top 10 Hldgs %
19.36%
Holding
1,672
New
551
Increased
173
Reduced
205
Closed
545
Top Buys
| 1 |
GE Aerospace
GE
|
+$22.9M |
| 2 |
Philip Morris
PM
|
+$22M |
| 3 |
Thermo Fisher Scientific
TMO
|
+$21.3M |
| 4 |
CRH
CRH
|
+$19.2M |
| 5 |
Banco Bradesco
BBD
|
+$18.9M |
Top Sells
| 1 |
Meta Platforms (Facebook)
META
|
+$29.6M |
| 2 |
Cisco
CSCO
|
+$17.8M |
| 3 |
Qiagen
QGEN
|
+$14M |
| 4 |
Coca-Cola
KO
|
+$13.7M |
| 5 |
Steris
STE
|
+$13.4M |
Sector Composition
| 1 | Healthcare | 28.96% |
| 2 | Technology | 22.18% |
| 3 | Financials | 12.68% |
| 4 | Industrials | 10.17% |
| 5 | Consumer Discretionary | 7.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
851
OrthoPediatrics
KIDS
$484M
| $2.86K | ﹤0.01% |
+133
| New | +$2.86K |
|
852
Trevi Therapeutics
TRVI
$1.17B
| $2.52K | ﹤0.01% |
+461
| New | +$2.52K |
|
853
Zevra Therapeutics
ZVRA
$448M
| $2.33K | ﹤0.01% |
+264
| New | +$2.33K |
|
854
LSI Industries
LYTS
$677M
| $2.31K | ﹤0.01% |
+136
| New | +$2.31K |
|
855
Foghorn Therapeutics
FHTX
$291M
| $2.26K | ﹤0.01% |
481
+105
| +28% | +$493 |
|
856
CS Disco
LAW
$343M
| $2.22K | ﹤0.01% |
509
+107
| +27% | +$468 |
|
857
Emerald Holding
EEX
$960M
| $2.2K | ﹤0.01% |
+453
| New | +$2.2K |
|
858
TTEC Holdings
TTEC
$179M
| $2.17K | ﹤0.01% |
+450
| New | +$2.17K |
|
859
PLAYSTUDIOS Inc
MYPS
$120M
| $2.13K | ﹤0.01% |
+1,628
| New | +$2.13K |
|
860
Aemetis
AMTX
$136M
| $2.02K | ﹤0.01% |
+816
| New | +$2.02K |
|
861
Liberty Global Class C
LBTYK
$3.99B
| $1.99K | ﹤0.01% |
+193
| New | +$1.99K |
|
862
First Western Financial
MYFW
$226M
| $1.8K | ﹤0.01% |
+80
| New | +$1.8K |
|
863
Mativ Holdings
MATV
$666M
| $1.79K | ﹤0.01% |
263
-15,970
| -98% | -$109K |
|
864
Telos
TLS
$469M
| $1.57K | ﹤0.01% |
+496
| New | +$1.57K |
|
865
Southern California Bancorp
BCAL
$558M
| $1.32K | ﹤0.01% |
+84
| New | +$1.32K |
|
866
Y-mAbs Therapeutics
YMAB
$390M
| $1.29K | ﹤0.01% |
287
-4,771
| -94% | -$21.5K |
|
867
Unity Bancorp
UNTY
$527M
| $1.22K | ﹤0.01% |
+26
| New | +$1.22K |
|
868
Alto Ingredients
ALTO
$89M
| $1.15K | ﹤0.01% |
1,003
+270
| +37% | +$310 |
|
869
Madrigal Pharmaceuticals
MDGL
$9.59B
| $1.13K | ﹤0.01% |
+4
| New | +$1.13K |
|
870
Century Therapeutics
IPSC
$43.9M
| $977 | ﹤0.01% |
+1,749
| New | +$977 |
|
871
Zymeworks
ZYME
$1.15B
| $966 | ﹤0.01% |
+77
| New | +$966 |
|
872
Orchestra BioMed
OBIO
$141M
| $949 | ﹤0.01% |
+354
| New | +$949 |
|
873
Cibus
CBUS
$73M
| $934 | ﹤0.01% |
+677
| New | +$934 |
|
874
Fulgent Genetics
FLGT
$667M
| $934 | ﹤0.01% |
47
-7,339
| -99% | -$146K |
|
875
Shattuck Labs
STTK
$83.8M
| $863 | ﹤0.01% |
+1,090
| New | +$863 |
|